GDF15 and obesity disorder: Non-alcoholic fatty liver disease (NAFLD), which reflects the degree of obesity and the risk for T2DM, is associated with increased expression and release of GDF-15, making it a potential biomarker for NAFLD and disease progression, particularly for worsening fibrosis and steatosis [23].